SLC5A2 and prostate carcinoma: Genetically proxied SGLT2 inhibition (estimated by primary instruments), equivalent to a one SD (0.62%) reduction in HbA1c, reduced the risk of total prostate cancer by 44% (odds ratio [OR] = 0.56, 95% CI = 0.38 to 0.82, p = 0.003; Tables 2 and S6).